論文 - 詳細
| RRC ID | 83110 |
|---|---|
| 著者 | Ohue Y, Kurose K, Nozawa R, Isobe M, Nishio Y, Tanaka T, Doki Y, Hori T, Fukuoka J, Oka M, Nakayama E. |
| タイトル | Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells. |
| ジャーナル | Cancer Immunol Res |
| Abstract |
The immune status of tumors varies, and this may affect the overall survival (OS) of patients. We examined tumors from 120 patients with lung adenocarcinomas with a tissue microarray for T-cell infiltration and the expression of PD-L1 and Galectin-9 (both ligands for inhibitory receptors on T cells), and cancer/testis (CT) antigen XAGE1 (GAGED2a; a tumor antigen often found on lung tumors) expression, to determine their relevance to OS. Patients defined as pStage I-IIIA could be grouped, based on the expression profiles of PD-L1, Galectin-9, and XAGE1, into cluster A, who had prolonged survival, and cluster B, who had shorter survival. The difference in survival of the clusters was confirmed separately for pStage I and pStage II-IIIA patients. Cluster A patients who also had CD4 and CD8 T-cell infiltration showed even better survival, as expected. The findings were confirmed by examining an independent validation cohort of 68 pStage I lung adenocarcinoma patients. Our data showed that PD-L1 expression was a positive indicator, whereas Galectin-9 and XAGE1 expression was negative. In vitro analyses suggested that PD-L1 expression was upregulated by IFNγ secreted from activated T cells in the tumor and Galectin-9 expression was counteracting those T cells. Thus, use of these immune markers enables the creation of a discriminant function with which to classify tumors and predict survival. Cancer Immunol Res; 4(12); 1049-60. ©2016 AACR. |
| 巻・号 | 4(12) |
| ページ | 1049-1060 |
| 公開日 | 2016-12-1 |
| DOI | 10.1158/2326-6066.CIR-15-0266 |
| PII | 2326-6066.CIR-15-0266 |
| PMID | 27799141 |
| MeSH | Adenocarcinoma / immunology Adenocarcinoma / metabolism* Adenocarcinoma of Lung Afatinib Antigens, Neoplasm / metabolism* B7-H1 Antigen / metabolism* Biomarkers, Tumor / metabolism CD4-Positive T-Lymphocytes / immunology CD4-Positive T-Lymphocytes / metabolism CD8-Positive T-Lymphocytes / immunology CD8-Positive T-Lymphocytes / metabolism Cell Line, Tumor ErbB Receptors / antagonists & inhibitors Galectins / metabolism* Humans Lung Neoplasms / immunology Lung Neoplasms / metabolism* Lymphocytes, Tumor-Infiltrating / immunology Lymphocytes, Tumor-Infiltrating / metabolism Quinazolines / pharmacology Receptor, ErbB-2 / antagonists & inhibitors Survival Analysis |
| IF | 8.728 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | PC-9(RCB4455) II-18(RCB2093) A549(RCB0098) HLC-1(RCB0083) Sq-1(RCB1905) EBC-1(RCB1965) RERF-LC-AI(RCB0444) |